Your session is about to expire
← Back to Search
Trilaciclib for Colorectal Cancer (PRESERVE1 Trial)
PRESERVE1 Trial Summary
This trial is testing the effects of a new drug on patients with a certain type of cancer who have not yet received treatment.
- Metastatic Colorectal Cancer
- Myelosuppression
- Chemotherapy Toxicity
PRESERVE1 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 1 & 2 trial • 122 Patients • NCT02499770PRESERVE1 Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is Trilaciclib used to treat?
"Trilaciclib can be used as a therapy for treating malignant neoplasms, bone marrow, and related procedures."
What does the scientific literature say about Trilaciclib's efficacy?
"8 studies are currently underway to assess the efficacy of Trilaciclib. Of these, 3 are Phase 3 clinical trials. However, because there are 408 total study locations, it is likely that one is near you."
Has Trilaciclib received government recognition in the United States?
"Our analysts have determined that Trilaciclib is safe enough to receive a 3 on our 1-to-3 scale. This is due to the fact that this is a Phase 3 trial, so there exists some evidence of efficacy in addition to multiple rounds of data affirming its safety."
Who else is applying?
What state do they live in?
How old are they?
What portion of applicants met pre-screening criteria?
What site did they apply to?
How many prior treatments have patients received?
How responsive is this trial?
Typically responds via
Most responsive sites:
- Beverly Hills Cancer Center: < 48 hours
Average response time
- < 2 Days
Share this study with friends
Copy Link
Messenger